Intravacc publishes 2022 annual report
Bilthoven, the Netherlands, 29 June 2023 – Intravacc B.V., a leading CDMO for infectious diseases and therapeutic vaccines, announced today the publication of its 2022 annual report and the appointment of Frieda Gerdes, PhD as Vice President Business Development and Marketing. On May 3rd the Dutch State announced the sale of Intravacc.
The comprehensive annual report for the financial year 2022, encompassing a thorough review of key figures, performance highlights, and financial statements for the period ending on December 31, 2022, is now available for download for further reference via the button underneath.
Intravacc is also pleased to announce the newly appointed Vice President Business Development & Marketing (VP BD&M) Mrs. Frieda Gerdes, PhD. Frieda, is a seasoned professional with over 25 years of experience in the healthcare industry. After receiving her PhD in cell biology from the University of Kiel in Germany, she began her career in 1996 in sales and has since held various leading positions in marketing and business development at companies such as ThermoFisher Scientific, Agendia, GE Healthcare, Epigenomics, and Molecular Health. In addition, Frieda has gained significant consulting and management expertise, supporting international diagnostic, pharma, and biotech companies in bringing innovative products to the market.
Intravacc is a state holding Company since 1 January 2021, under the Ministry of Health, Welfare & Sports (VWS). In 2019 the privatization of Intravacc was initiated by the Ministry. Due to the COVID pandemic the sale of the company was postponed. In April 2022 the Minister of Health decided to re-start the sales process of the Company and on May 3rd 2023 the sales process formally started. The Dutch State intends to sell 100% of the issued and outstanding shares in Intravacc B.V. through a controlled auction process. This was a great step forward for the Company and all its employees. Once a new owner of the company has been secured, Intravacc can fast track its current strategy to become one of the leading CDMOs within the global vaccine industry.
Dr. Jan Groen, Intravacc’s CEO, said:
“In 2022 we added nine new business contracts with a total book value of € 34 million. In the beginning of 2023 we also signed our first therapeutic vaccine development contract with a value of € 3.5 million. This increase in new business within two years after the inception as a private CDMO company on January 1st 2021 is an amazing achievement for the company. With the further expansion of our commercial team and the operational improvements within the company we are well-postioned to become a global leader amongst CDMOs in the vaccine industry”
